Mechanistic and Structural Insights on Difluoromethyl-1,3,4-oxadiazole Inhibitors of HDAC6.
DFMO hydrolysis
LC-MS
NMR
X-ray crystallography
difluoroacetylhydrazide (DFAcH)
difluoromethyl-1,3,4-oxadiazole (DFMO)
enzyme kinetics
histone deacetylase 6 (HDAC6)
non hydroxamic inhibitors
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
28 May 2024
28 May 2024
Historique:
received:
24
04
2024
revised:
20
05
2024
accepted:
22
05
2024
medline:
19
6
2024
pubmed:
19
6
2024
entrez:
19
6
2024
Statut:
epublish
Résumé
Histone deacetylase 6 (HDAC6) is increasingly recognized for its potential in targeted disease therapy. This study delves into the mechanistic and structural nuances of HDAC6 inhibition by difluoromethyl-1,3,4-oxadiazole (DFMO) derivatives, a class of non-hydroxamic inhibitors with remarkable selectivity and potency. Employing a combination of nuclear magnetic resonance (NMR) spectroscopy and liquid chromatography-mass spectrometry (LC-MS) kinetic experiments, comprehensive enzymatic characterizations, and X-ray crystallography, we dissect the intricate details of the DFMO-HDAC6 interaction dynamics. More specifically, we find that the chemical structure of a DMFO and the binding mode of its difluoroacetylhydrazide derivative are crucial in determining the predominant hydrolysis mechanism. Our findings provide additional insights into two different mechanisms of DFMO hydrolysis, thus contributing to a better understanding of the HDAC6 inhibition by oxadiazoles in disease modulation and therapeutic intervention.
Identifiants
pubmed: 38892072
pii: ijms25115885
doi: 10.3390/ijms25115885
pii:
doi:
Substances chimiques
Oxadiazoles
0
Histone Deacetylase 6
EC 3.5.1.98
Histone Deacetylase Inhibitors
0
HDAC6 protein, human
EC 3.5.1.98
1,3,4-oxadiazole
20O2F20OUR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM